BINDU DONOVAN is a partner in the firm’s Intellectual Property Litigation practice. Bindu has more than 15 years of experience representing some of the world’s leading life sciences companies in complex patent litigation. Bindu’s practice focuses on pharmaceutical and medical device litigation, and she has substantial experience with cases brought under the Hatch-Waxman Act. Bindu has successfully represented clients in patent litigation involving small molecule drugs, drug-eluting stents, chemical compositions, photodynamic therapy and biotechnology. Bindu also counsels clients on intellectual property issues.
Bindu was named as one of the Top 250 Women in Litigation by Benchmark Litigation (2015, 2014 and 2013), a publication honoring the achievements of female lawyers in litigation practices in the United States. She was also recognized for her life sciences-related patent work as a nominee for the “Rising Star-IP” award at the 2013 Americas Women in Business Law Awards and was also named a “Life Sciences Star” in the 2014 and 2013 editions of LMG Life Sciences.
- Gilead Sciences, Inc., Hoffmann-LaRoche Inc., and Genentech, Inc. et al., v. Natco Pharma (D.N.J.) - (counsel for Gilead and Roche/Genentech) in patent infringement suit involving antiviral drug Tamiflu®)
- Cordis Corporation and Wyeth v. Abbott (D.N.J.); Cordis Corporation and Wyeth v. Abbott, Boston Scientific and Medtronic (D.N.J.); Boston Scientific v. Johnson & Johnson, Cordis Corporation and Wyeth (D. Del.) – (counsel for patent holders Cordis and Wyeth in series of patent infringement suits involving drug eluting stents)
- L’Oreal v. Johnson & Johnson (D. Del.) – (counsel for defendant Johnson & Johnson in action involving patents relating to chemical compositions for sunscreen products)
- Noven Pharmaceuticals, Inc. v. Watson (D.N.J.) – (counsel for patent holder Noven Pharmaceuticals in patent infringement litigation filed under the Hatch-Waxman Act concerning transdermal patch for ADHD, Daytrana®)
- Eli Lilly and Company v. Actavis (D.N.J.) and Eli Lilly and Company v. Synthon (E.D. Va.) – (counsel for patent holder Eli Lilly in patent infringement litigations filed under the Hatch-Waxman Act concerning ADHD drug, Strattera®)
- SmithKline Beecham PLC v. Teva and Dr. Reddy’s Laboratories (D.N.J.) – (counsel for patent holder SmithKline Beecham in patent infringement litigations filed under the Hatch-Waxman Act concerning Type 2 diabetes drug Avandia®)
- Massachusetts Eye and Ear Infirmary v. QLT (1st Cir.) – (counsel for MEEI in successful appeal from district court’s grant of summary judgment in case involving inter alia, unjust enrichment, trade secret misappropriation, and unfair trade practice claims arising out of inventorship dispute concerning ophthalmic drug Visudyne®)*
- Massachusetts Eye and Ear Infirmary v. Novartis Ophthalmics and QLT (D. Mass.) – (counsel for patent holder MEEI in patent infringement litigation concerning Visudyne®)*
*Matters handled prior to joining Sidley
Bindu serves on the firm’s Committee for the Assignment and Compensation of Associates and the Diversity Committee. Bindu is also a member of the American Bar Association, the New York Intellectual Property Law Association and the New York State Bar Association.
- “Making Your Case: Effectively Using Experts in Patent Litigation,” NYIPLA CLE Luncheon (New York, NY, February 28, 2013).
- “Hatch Waxman Litigation,” NJIPLA: Patent Law and Pharmaceuticals Symposium (Newark, NJ, October 12, 2011).
- “Ensuring Global Success: Clinical Trial and IP Law & Strategy In Emerging Markets,” BioNJ Legal Forum, (Nutley, NJ, November 18, 2010).
- “Trends and Developments in US Pharmaceutical and Biotech Patent Law” and “US Patent Law Reform: The Patent Reform Act of 2007,” Pharmaceutical Patent Litigation Strategies 2008, Pharma IQ, IQPC (London, UK, March 31 - April 1, 2008).
- “Developments In Claim Interpretation,” The Federal Circuit Turns 25: Federal Circuit Judges and Practitioners Describe Its Accomplishments; Also: Tips for Federal Circuit Advocacy, Association of the Bar of the City of New York (New York, NY, October 4, 2007).